LEQEMBI IQLIK (lecanemab-irmb) subcutaneous initiation regimen
Alzheimer's disease · Adults with mild cognitive impairment or mild dementia due to Alzheimer's disease
BIIB · Biogen
規制上の指定
全タイムライン
7 件のマイルストーンOriginal PDUFA date superseded by early approval
FDA had extended the PDUFA action date from May 24 to August 24 after determining that additional information submitted during review constituted a major amendment. The agency approved the sBLA on July 13, before the revised goal date.
Eisai — PDUFA review extension to August 24↗FDA approved subcutaneous initiation dosing
FDA approved LEQEMBI IQLIK as a once-weekly subcutaneous initiation regimen for early Alzheimer's disease. The approved 500 mg starting dose is administered as two 250 mg autoinjector injections.
Eisai — FDA approval of LEQEMBI IQLIK initiation dosing↗FDA extended the review by three months
FDA requested additional information and treated the response as a major amendment, moving the PDUFA action date from May 24 to August 24, 2026. Eisai and Biogen said FDA had not raised approvability concerns at that time.
Biogen — FDA Priority Review extension↗FDA accepted the sBLA with Priority Review
FDA accepted the sBLA for LEQEMBI IQLIK as a weekly subcutaneous starting dose and initially assigned a May 24, 2026 PDUFA action date. The application was supported by subcutaneous dosing data, including Phase 3 Clarity AD open-label extension substudies.
Eisai — sBLA acceptance and Priority Review↗関連ニュース
Biogen Completes Acquisition of RayThera Inc.
2026年7月15日Biogen Appoints Michael J. Parini as Chief Legal Officer
2026年7月14日LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
2026年7月14日Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
2026年7月13日FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease